Granules India signs MOU with PharmaMatch
PharmaMatch B.V. and Granules India Limited are pleased to announce the signing of a Memorandum of Understanding to develop, manufacture and market formulations in the European Market jointly.
This arrangement will kick-off with the transfer of existing marketing authorizations by PharmaMatch to Granules for products like Paracetamol where Granules has the basic and the necessary skill sets to deliver the same. This will use the upcoming finished dosage facility of Granules which is expected to be commissioned and fully operational by May 2007.
Commenting on the development, Mr. Irfan Vazirally, Executive Director, PharmaMatch India, said, “Granules has demonstrated excellent capabilities in pharmaceutical manufacturing and they are counting on their capabilities to take this forward in their new business of finished dosages as well”.
Mr. C. Krishna Prasad, Managing Director, Granules India Ltd. said, “PharmaMatch is a renowned finished dosage player in European Union and we expect this relationship to catapult Granules strongly into the European Market. We are expecting this development to expedite the approval process for the finished dosage facility in the European Union”.
Sourced From: Adfactors Public Relations Pvt Ltd
Granules India stock price
On August 22, 2014, Granules India closed at Rs 771.90, up Rs 41.40, or 5.67 percent. The 52-week high of the share was Rs 779.00 and the 52-week low was Rs 127.00.
The company's trailing 12-month (TTM) EPS was at Rs 43.46 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 17.76. The latest book value of the company is Rs 168.89 per share. At current value, the price-to-book value of the company is 4.57.
READ MORE ON PharmaMatch B.V, Granules India Limited , Memorandum of Understanding , develop, manufacture , market formulations , European Market , Paracetamol, Irfan Vazirally, pharmaceutical manufacturing , dosages , C. Krishna Prasad
Set email alert for
ADS BY GOOGLE
video of the day
See earnings growth spike, big reforms in 2015: Envision